Market Research Report
Global Clinical Trials Market, By Type, By Phase, By Study Design, By Indication, By End User, By Company, By Region, Forecast & Opportunities, 2026
|Published by||TechSci Research||Product code||1002692|
|Published||Content info||113 Pages
Delivery time: Inquiry
|Global Clinical Trials Market, By Type, By Phase, By Study Design, By Indication, By End User, By Company, By Region, Forecast & Opportunities, 2026|
|Published: April 28, 2021||Content info: 113 Pages||
Global Clinical Trials Market, By Type (Pharmaceutical Trials Vs Medical Device Trials), By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Autoimmune/Inflammation, Oncology, CNS, Diabetes, Cardiovascular, Others), By End User (Clinical Research Organizations, Pharmaceutical and Biotechnological Companies, Clinical Testing Laboratories, Others), By Company, By Region, Forecast & Opportunities, 2026.
Global clinical trials market was valued at USD51.25 billion in 2020 and is anticipated to reach USD77.20 billion by 2026, registering a CAGR of 7.10% in the next five years. The market is driven by the outbreak of tropical and infectious diseases such as COVID-19, which has led to extensive clinical trials around the world in order to find the suitable treatment and vaccine. The growing adoption of virtual clinical trials that allow to collect data efficiently and safely from participants without the requirement of traveling to the lab or hospital is also acting as a major growth driver for the global clinical trials market. Moreover, the growing prevalence of neurological diseases such as Parkinson's, Alzheimer's and depression, coupled with growing geriatric population are some other key factors creating the need for clinical trials. Also, the digitization of clinical trials is anticipated to propel the growth of this market in the coming years.
Additionally, the increasing prevalence of chronic diseases and growing need for personalized drugs are some other key factors propelling the growth of the global clinical trials market. Governments in various economies are also providing favorable support for clinical trials in order to find the cure for deadly diseases like coronavirus. The increasing expenditure on R&D activities and rise in biotechnology firms is also anticipated to drive the market growth through 2026.
Global clinical trials market can be segmented based on type, phase, study design, indication, end user and region. Based on indication, the market can be segmented into autoimmune/inflammation, oncology, CNS, diabetes, cardiovascular and others. Among these, the oncology segment dominated the market until 2020 and is expected to maintain its dominance during the forecast period as well owing to increasing expenditure by the medical industry towards preclinical and clinical development of oncology drugs.
Regionally, Asia Pacific is anticipated to witness the fastest CAGR through 2026 owing to a large patient pool suffering from coronavirus and increasing number of biotechnology firms undergoing COVID-19 trials. The favorable support by governments in countries such as India and South Korea is also leading to extensive clinical trials in the two countries.
Major companies operating in the global clinical trials market include: Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Novo Nordisk A/S, Pfizer Inc., GlaxoSmithKline plc, ICON plc, Pharmaceutical Product Development Inc., F. Hoffmann-La Roche AG, IQVIA Holdings Inc., Covance Inc., Syneos Health Inc., PRA Health Sciences Inc., Medpace Holdings, Inc., WuXi Apptec Company Ltd., Thermo Fisher Scientific Inc., among others. The market players are undertaking growth strategies such as mergers and acquisitions along with new product launches to increase their share in the global clinical trials market.
Years considered for this report:
Historical Years: 2016-2019
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2022-2026
Objective of the Study:
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of CROs across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.
TechSci Research calculated global clinical trials market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.
Key Target Audience:
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as clinical trials service provider companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
In this report, the global clinical trials market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Medical Device Trials
Clinical Research Organizations
Pharmaceutical and Biotechnological Companies
Clinical Testing Laboratories
Middle East & Africa
Company Profiles: Detailed analysis of the major companies present in the global clinical trials market.
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Profit Margin Analysis: